Mongolia vs Uganda: Average cost of drugs for extensively drug-resistant tuberculosis
Mongolia
1,900 constant 2022 US$
in 2024
Uganda
1,709 constant 2022 US$
in 2024
Mongolia rank
28th
Uganda rank
30th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mongolia
- Uganda
How they compare
Mongolia currently reports 1,900 constant 2022 US$ against 1,709 constant 2022 US$ in Uganda, a difference of 191 constant 2022 US$.
That makes Mongolia's figure about 1.1 times Uganda's.
The two have swapped places 2 times across 8 shared years of data; in 2017 it was Mongolia ahead.
Mongolia ranks 28th and Uganda ranks 30th of 56 countries.
Across the 2 decades both report, Mongolia averaged higher in 1 and Uganda in 1.
Head to head by decade
| Decade | Mongolia | Uganda | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 14,667 constant 2022 US$ | 3,356 constant 2022 US$ | 11,311 constant 2022 US$ | Mongolia |
| 2020s | 2,120 constant 2022 US$ | 3,247 constant 2022 US$ | 1,127 constant 2022 US$ | Uganda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mongolia or Uganda?
- Mongolia, at 1,900 constant 2022 US$ against 1,709 constant 2022 US$ in Uganda as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mongolia and Uganda?
- 191 constant 2022 US$, with Mongolia ahead.
- How many years of comparable data are there for Mongolia and Uganda?
- 8 years are reported by both, from 2017 to 2024.
- How do Mongolia and Uganda rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mongolia ranks 28th and Uganda ranks 30th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.